We have designed our proprietary RED PLATFORM™ to genetically engineer and culture Red Cell Therapeutics, also called RCTs, that express biotherapeutic proteins within or on the surface of the cell. This results in highly potent, well tolerated and ready-to-use cellular medicines for the potential treatment of a range of diseases.
The fundamental and potent biology of the underlying platform potentially will allow us to manufacture missing enzymes for patients living with enzymatic rare diseases, kill tumors in cancer and regulate the immune system for the treatment of autoimmune diseases.
- From a single O- blood donor we can generate enough doses to potentially treat hundreds to thousands of individual patients
- From one consistent manufacturing process we can generate a broad pipeline of RCTs, changing only the gene cassettes that encode the biotherapeutic proteins from drug to drug
Our RED PLATFORM™ and RCT™ product candidates potentially represent a transformative step in the evolution of cellular therapies and are designed to provide the following attributes:
Our initial focus is to advance RCT program candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction.